Evaluating the miR-302b and miR-145 expression in formalin-fixed paraffin-embedded samples of esophageal squamous cell carcinoma

Archives of Iranian Medicine

Volumn 18, Issue 3, 2015, Pages 173-178

  Tabrizi, Mojtaba ^a   Khalili, Mitra ^b   Vasei, Mohammad ^c   Nouraei, Nazila ^a   Mansour Samaei, Nader ^d   Khavanin, Ali ^e   Khajehei, Mehrdad ^f   Mowla, Seyed Javad ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Esophageal cancer; FFPE; Hsa miR 145; Hsa miR 302b; Molecular marker

Indexed keywords

MICRORNA; MICRORNA 145; MICRORNA 302B; UNCLASSIFIED DRUG; MIRN145 MICRORNA, HUMAN; MIRN302 MICRORNA, HUMAN; PARAFFIN; TUMOR MARKER;

ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; GENETICS;

BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; HUMANS; MICRORNAS; PARAFFIN EMBEDDING; REAL-TIME POLYMERASE CHAIN REACTION; ROC CURVE;

EID: 84924411427     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Enzinger PC, MayerRJ. Esophageal Cancer. N Engl J Med. 2003;349(23): 2241-2252.
2. Kollarova H, Machova L, Horakova D, Janoutova G, Janout V. Epidemiology of esophageal cancer-an overview article. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151(1): 17-20.
3. Bohanes P, Yang D, Chhibar RS, Labonte MJ, Winder T, Ning Y, et al. Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol. 2012;30(18): 2265-2272.
4. Steyerberg EW, Neville B, Weeks JC, Earle CC. Referral patterns, treatment choices, and outcomes in locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol. 2007;25(17): 2389-2396.
5. Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer. 2002;95(7): 1434-1443.
6. Bollschweiler E, Wolfgarten E, Nowroth T, Rosendahl U, Mönig SP, Hölscher AH. Vitamin intake and risk of subtypes of esophageal cancer in Germany. J Cancer Res Clin Oncol. 2002;128(10): 575-580.
7. Sepehr A, Kamangar F, Fahimi S, Saidi F, Abnet CC, Dawsey SM. Poor oral health as a risk factor for esophageal squamous dysplasia in northeastern Iran. Anticancer Res. 2005; 25(1B): 543-546.
8. Mohebbi M, Mahmoodi M, Wolfe R, Nourijelyani K, Mohammad K, Zeraati H, et al. Geographical spread of gastrointestinal tract cancer incidence in the Caspian Sea region of Iran: spatial analysis of cancer registry data. BMC Cancer. 2008;8: 137.
9. Crehange G, Bonnetain F, Peignaux K, True G, Blanchard N, Rat P, et al. Preoperative radiochemotherapy for resectable localised oesophageal cancer: a controversial strategy. Crit Rev Oncol Hematol. 2010;75(3): 235-242.
10. George G, Mittal RD. MicroRNAs: Potential biomarkers in cancer. Indian J Clin Biochem. 2010;25(1): 4-14.
11. Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM. Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta. 2014;1845(2): 255-265.
12. Hayes J, Peruzzi P, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8): 460-469.
13. Barroso-del Jesus A, Romero-López C, Lucena-Aguilar G, Melen GJ, Sanchez L, Ligero G, et al. Embryonic stem cell-specific miR302-367 cluster: human gene structure and functional characterization of its core promoter. Mol Cell Biol. 2008;28(21): 6609-6619.
14. Card DA, Hebbar PB, Li L, Trotter KW, Komatsu Y, Mishina Y, et al. Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. Mol Cell Biol. 2008;28(20): 6426-6438.
15. Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer. 2009; 9: 374.
16. Cui SY, Wang R, Chen LB. MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways. J Cell Mol Med. 2014;18(10): 1913-1926.
17. Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S, et al. miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer. 2014;13: 220.
18. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009. 137(4): 647-658.
19. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, et al.P53 represses c-Myc through induction of the tumor suppressor miR-145. Pwc Natl Acad Sci USA. 2009;106(9): 3207-3212.
20. Navarro A, Monzo M. MicroRNAs in human embryonic and cancer stem cells. Yonsei Med J. 2010;51(5): 622-632.
21. Chivukula, RR, Mendell JT, Abate and switch: miR-145 in stem cell differentiation. Cell. 2009;137(4): 606-608.
22. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002.12(9): 735-739.
23. Palmer RD, Murray MJ, Saini HK, van Dongen S, Abreu-Goodger C, Muralidhar B, et al. Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res. 2010. 70(7): 2911-2923.
24. Murray MJ, Saini HK, van Dongen S, Palmer RD, Muralidhar B, Pett MR, et al. The two most common histological subtypes of malignant germ cell tumour are distinguished by global microRNA profiles, associated with differential transcription factor expression. Mol Cancer. 2010;9: 290.
25. Lin SL, Chang DC, Ying SY, Leu D, Wu DT. MicroRNA miR-302 inhibits the tumorigenecity of human piuripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res. 2010;70(22): 9473-9482.
26. Kha Jili M, Sadeghizadeh M, Alimoghaddam K, Malekzadeh R, Vasei M, Mowla SJ. Down-regulation of miR-302b, an ESC-specific microRNA, in Gastric Adenocarcinoma. Cell Journal (Yakhteh). 2011;13(4): 251-258.
27. Zhu K, Pan Q, Jia LQ, Dai Z, Ke AW, Zeng HY, et al. MiR-302c inhibits tumor growth of hepatocellular carcinoma by suppressing the endothelial-mesenchymal transition of endothelial cells. Sci Re. 2014;4: 5524.
28. Wang L, Yao J, Shi X, Hu L, Li Z, Song T, et al. MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells. BMC Cancer. 2013;13: 448.
29. Tang KH, Dai YD, Tong M, Chan YP, Kwan PS, Fu L, et al. A CD90(+) tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer. Cancer Res. 2013;73(7): 2322-2332.
30. Zhao JS, Li WJ, Ge D, Zhang PJ, Li JJ, Lu CL, et al. Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. PLoS One. 2011;6(6): e21419.
31. Rafiee MR, Malekzadeh Shafaroudi A, Rohban S, Khayatzadeh H, Kalhor HR, Mowla SJ. Enrichment of arare subpopulation of miR-302-expressing glioma cells by serum deprivation. Cell J. 2015; 16(4): 494-505.
32. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16): 7065-7070.
33. Akao Y, Nakagawa Y, NaoeT. MicroRNA-143 and-145 in colon cancer. DNA Cell Biol. 2007;26(5): 311-320.
34. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008;27(12): 1788-1793.
35. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T. Downregulation of microRNAs-143 and-145 in B-cell malignancies. Cancer Sci. 2007;98(12): 1914-1920.
36. Khalili M, Sadeghizadeh M, Alimoghaddam K, Malekzadeh R, Khalili D, Edalat R, et al. MiR-145 and P21, two direct targets of P53, are down-regulated in gastric cancer. In: New Horizons in Cancer Research: Biology to Prevention to Therapy. 2011 Dec 13-16; Delhi, India: AACR; 2011. p 113. Abstract No B70.
37. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009;125(2): 345-352.
38. Khalili M, Vasei M, Khalili D., Alimoghaddam K, Sadeghizadeh M, Mowla S J. Dow nregulation of the Genes Inv olv ed in Reprogramming (SOX2, c-MYC, miR-302, miR-145, and P21) in Gastric Adenocarcinoma. J Gastrointest Cancer. Accepted 2015.
39. Wu BL, Xu LY, Du ZP, Liao LD, Zhang HF, Huang Q, et al. MiRNA profile in esophageal squamous cell carcinoma: downregulation of miR-143 and miR-145. World J Gastroenterol. 2011;17(1): 79-88.
40. Liu R, Liao J, Yang M, Sheng J, Yang H, Wang Y, et al. The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLoS One. 2012;7(3): e33987.
41. Nouraee N, Van Roosbroeck K, Vasei M, Semnani S, Samaei NM, Naghshvar F, et al. Expression, tissue distribution and function of miR-21 in esophageal squamous cell carcinoma. PLoS One. 2013;8(9): e73009.
42. Kurashige J, Kamohara H, Watanabe M, Tanaka Y, Kinoshita K, Saito S, et al. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. JSurg Oncol. 2012;106(2): 188-192.